spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

ICON Releases Environmental, Social and Governance Report

ICON plc

The report looks to the future of ESG for the new ICON while highlighting advancements made in 2020

 


 

Dublin, Ireland, November 22, 2021ICON plc (NASDAQ: ICLR) announced today the release of its 2020 Environmental, Social and Governance (ESG) Report. With the completion of ICON’s acquisition of PRA Health Sciences, the report presents a unified overview of the ESG advancements of both legacy organisations during 2020 and sets out the commitments, policies, and outlook for the combined company.

The ESG Report is available at: https://www.iconplc.com/about/esg/

“As a combined company, new ICON is focused on continuing to develop its ESG strategy and initiatives,” said ICON CEO Steve Cutler. “This report may be a look back to 2020, but it also demonstrates the great promise of the two organisations joining together to become the healthcare intelligence partner of choice. New ICON will continue to make a positive social and environmental impact and pursue our ESG goals and targets.”

For more information about ICON’s ESG efforts, please visit https://www.iconplc.com/about/esg/

phone +353 1 291 2883
email info-clinical@iconplc.com
web www.iconplc.com
email ICON plc, Headquarters, South County Business Park, Leopardstown, Dublin 18, Ireland
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Generis Appoints Head of Life Sciences as CARA™ Growth Soars

London, UK – January 27th, 2022 - Generis, the creator of CARA™, the data and content management platform that helps life sciences companies transform their complex business processes, has created a new Head of Life Sciences role and appointed Mark Willoughby, a deeply experienced Regulatory and Quality expert. He will direct both onward platform and application development and drive new growth for Generis’s CARA™ Life Science platform.
More info >>


White Papers

Backward Thinking: The Reverse Engineering of A Pressurized Metered Dose Inhaler

Development of a generic equivalent to a current marketed pressurized metered dose inhaler (pMDI) product brings immense challenges. Thorough analysis is critical to gain a comprehensive understanding of the physical attributes and pharmaceutical performance of the reference marketed product. Many factors need to be assessed, understood and combined in order to successfully develop a generic pMDI which will meet the regulatory and quality requirements as an equivalent product in the anticipated target market. Significant information about the reference marketed product can be obtained from a thorough review of published literature, specifically the Summary of Product Characteristics (SPC) and Patient Information Leaflet (PIL). Additionally, baselining the reference marketed product for pharmaceutical performance offers a working target specification for in-vitro correlation. It will ensure the smoothest possible path to commercialization and maximize return on investment. In addition, baselining of the reference marketed product is done to understand batch-to-batch variability and product performance over the stated shelf life to establish targets for critical quality attributes (CQAs), which can be applied to the generic equivalent pMDI.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement